Literature DB >> 26808370

Safety and Efficacy Outcomes of Home and Hospital Warfarin Management Within a Pediatric Anticoagulation Clinic.

Sophie Jones1, Siobhan McLoughlin, Dana Piovesan, Helen Savoia, Paul Monagle, Fiona Newall.   

Abstract

The complexity of managing children with chronic disease has led to an increase in the use of long-term warfarin therapy. Time in therapeutic range (TTR) is the preferred method for determining efficacy and stability of warfarin management. This study aimed to determine the TTR achievement and incidence of adverse events among pediatric warfarin patients managed by an anticoagulation clinic over 12 months and to compare TTR achievement between patients self-testing (PST) at home and those monitored using routine methods. International normalized ratio (INR) results reported for 2012 for children currently having their warfarin therapy managed by a dedicated pediatric anticoagulation clinic were analyzed. Warfarin-related adverse events were recorded. A total of 164 patients were included. In total, 93 children performed PST and 71 children tested their INR at a hospital or pathology service. TTR achievement for the cohort was 67.1% (95% confidence interval, 64.4-69.7). A total of 69.2% of INR tests conducted at home were within the TTR compared with 64.3% of INR tests conducted at a hospital or pathology service (P=0.07). One major bleeding event occurred and there was 1 thrombotic episode. PST demonstrated noninferior warfarin stability compared with routine methods. Routine outcome evaluation of pediatric anticoagulation management within single institutions is necessary to confirm the success of such programs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26808370     DOI: 10.1097/MPH.0000000000000502

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

Review 1.  Management of thrombosis in children and neonates: practical use of anticoagulants in children.

Authors:  Paul Monagle; Fiona Newall
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  UNUSUAL WARFARIN DOSE TO ACHIEVE THERAPEUTIC INR IN A 4-MONTH OLD CHILD: NON-GENETICS RISK FACTORS ARE STILL A CHALLENGE.

Authors:  Lucas Miyake Okumura; Giovanna Webster Negretto; Clarissa Gutiérrez Carvalho
Journal:  Rev Paul Pediatr       Date:  2017 Oct-Dec

3.  Personalised Warfarin Dosing in Children Post-cardiac Surgery.

Authors:  Basma Zuheir Al-Metwali; Peter Rivers; Larry Goodyer; Linda O'Hare; Sanfui Young; Hussain Mulla
Journal:  Pediatr Cardiol       Date:  2019-10-05       Impact factor: 1.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.